Last Update Time:
20-Mar-2025 16:00:00
ISIN:
INE182A01018
Sector:
Healthcare
Symbol:
PFIZER
Pfizer Limited
₹4,120.00
₹51.85
(1.27%)
▲
Prev. Close
₹4,068.15
Open
₹4,072.10
Close
₹4,115.35
Range
₹3,914.00 - ₹4,326.00
High
₹4,165.80
Low
₹4,065.05
Ind. Close
₹0.00
VWAP
₹4,105.80
The current stock price of Pfizer Limited is ₹4,120.00, with a target price range between ₹3,914.00 and ₹4,326.00. The stock has experienced a price change of ₹51.85 (1.27%), reflecting recent market volatility.
Today's opening price was ₹4,072.10, while the previous close stood at ₹4,068.15.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Pfizer Limited Price Chart
Pfizer Limited Pre Open Market Overview: 20-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 4072.1
- Previous Close Price: 4068.15
- Change: 3.95%
- Total Traded Volume: 15
- Total Buy Quantity: 1,078
- Total Sell Quantity: 2,005
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 4,068.40 | 4.00 | 0.00 |
| 4,070.00 | 25.00 | 0.00 |
| 4,071.00 | 3.00 | 0.00 |
| 4,072.00 | 6.00 | 0.00 |
| 4,072.10 | 9.00 | 0.00 |
| 4,078.25 | 0.00 | 2.00 |
| 4,078.30 | 0.00 | 2.00 |
| 4,080.00 | 0.00 | 3.00 |
| 4,088.40 | 0.00 | 2.00 |
| 4,088.50 | 0.00 | 2.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 4,115.35 | 9 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 1078
Total Sell Quantity: 2005
Shareholding Patterns of Pfizer Limited
Key Trade Statistics of Pfizer Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.31 |
| Traded Value (₹ Cr.) | 12.58 |
| Total Market Cap (₹ Cr.) | 18,848.07 |
| Free Float Market Cap (₹ Cr.) | 6,237.54 |
| Impact cost | 0.06 |
| Quantity Traded | 30,645.00 |
| Deliverable Quantity | 16,746.00 |
| % of Quantity to Traded | 54.65 |
| Security VaR | 10.49 |
| Index VaR | N/A |
| VaR Margin | 10.49 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 13.99 |
| Face Value | 10 |
Key Price Statistics of Pfizer Limited
The 52-week high for Pfizer Limited was ₹6,451.15, recorded on 02-Sep-2024. On the other hand, the 52-week low stands at ₹3,865.00, with the lowest value recorded on 04-Mar-2025.
The upper band for trading is ₹4,881.75, and the lower band is ₹3,254.55. The price band is 20%.
The stock's daily volatility stands at 1.66, while the annualized volatility is 31.71. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (02-Sep-2024) | 6,451.15 |
| 52 Week Low (04-Mar-2025) | 3,865.00 |
| Upper Band | 4,881.75 |
| Lower Band | 3,254.55 |
| Price Band (%) | 20 |
| Daily Volatility | 1.66 |
| Annualised Volatility | 31.71 |
| Tick Size | 0.05 |
Key Securities Statistics of Pfizer Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 28-Apr-1999 |
| Adjusted P/E | 30.24 |
| Symbol P/E | 30.24 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Pfizer Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Pfizer Limited
| Subject | Date |
|---|---|
| Outcome of Board Meeting | 21-Feb-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 14-Feb-2025 |
| General Updates | 14-Feb-2025 |
| General Updates | 05-Feb-2025 |
| General Updates | 05-Feb-2025 |
| Action(s) initiated or orders passed | 04-Feb-2025 |
| Action(s) initiated or orders passed | 03-Feb-2025 |
| Integrated Filing- Financial | 01-Feb-2025 |
Corporate Actions of Pfizer Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 10 | Dividend - Rs 35 Per Share | 21-Aug-2024 |
| 10 | Dividend - Rs 35 Per Share/ Special Dividend - Rs 5 Per Share | 11-Aug-2023 |
| 10 | Special Dividend - Rs 30 Per Share | 19-Sep-2022 |
| 10 | Dividend - Rs 35 Per Share | 18-Aug-2022 |
| 10 | Annual General Meeting/Dividend - Rs 30 Per Share/Special Dividend - Rs 5 Per Share | 11-Aug-2021 |
| 10 | Annual General Meeting/Dividend - Rs 10 Per Share | 27-Aug-2020 |
| 10 | Special Dividend - Rs 320 Per Share | 06-May-2020 |
| 10 | Dividend - Rs 22.50 Per Share | 01-Aug-2019 |
| 10 | Annual General Meeting/Dividend- Rs 20 Per Share | 29-Aug-2018 |
| 10 | Dividend Rs 15/- Per Share + Special Dividend Rs 5/- Per Share | 22-Aug-2017 |
| 10 | Dividend - Rs.15/- Per Share | 27-Jun-2016 |
| 10 | Annual General Meeting And Dividend Rs.12.50 Per Share | 03-Jul-2015 |
| 10 | Annual General Meeting | 29-Oct-2014 |
| 10 | Interim Dividend - Rs 360/- Per Share | 05-Dec-2013 |
| 10 | Annual General Meeting / Dividend - Rs 12.50/- Per Share + Special Dividend - Rs 20/- Per Share | 28-Aug-2013 |
| 10 | Annual General Meeting/ Dividend Rs 12.50 Per Share | 24-Jul-2012 |
| 10 | Dividend-Rs.4/- Per Share | 08-Jul-2011 |
| 10 | Interim Dividend-Rs.12.50 Per Share | 20-Jan-2011 |
| 10 | Div-Rs.12.50 Per Share | 15-Apr-2010 |
| 10 | Dividend-Rs.12.50/ Per Sh | 31-Mar-2009 |
Board Meetings of Pfizer Limited
Financial Results of Pfizer Limited
Company Directory of Pfizer Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.pfizerindia.com | Registered Office | The Capital, 1802/1901, Plot No.C-70, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400 051. | MUMBAI |
| www.pfizerindia.com | Transfer Agent | KFin Technologies Limited Selenium, Tower B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally Hyderabad Rangareddi | HYDERABAD |
Insider Trading of Pfizer Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Anil Gupta | 105000 | Buy |
| 7(2) | Anil Gupta | 659000 | Sell |
| 7(2) | Anil Gupta | 514500 | Buy |
| 7(2) | Anil Gupta | 405000 | Buy |
| 7(2) | Anil Gupta | 101951 | Buy |
Annual Reports of Pfizer Limited
Investor Complaints of Pfizer Limited
Event Calendar of Pfizer Limited
| Purpose | Details |
|---|---|
| Financial Results | The Company proposes to reconsider the audited Financial Results of the merged entity i.e. Pfizer Ltd. and Duchem Laboratories Ltd. A meeting of the Board of Directors of Pfizer Ltd. would be held on March 19, 2010, to reconsider and approve the Annual Financial Results of the merged entity with a view to give effect to the Court order. |
| Results/Dividend | The Company had informed the Exchange regarding a Board Meeting to be held on Januray 11, 2011 to Inter-alia consider and approve the Unaudited Financial Results for the 4th Quarter ended November 30, 2010. The Company has now informed the Exchange that the Board of Directors of the Company will also consider declaration of an interim dividend at the said meeting. (purpose revised) |
| Results/Dividend | Inter-alia to consider and approve the Audited Financial Results of the Company for the 16 months period December 01, 2009 to March 31, 2011 and to recommend final dividend, thereon, if any. |
| Results/Dividend | Inter alia to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012 and to recommend dividend thereon. |
| Results | Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2012. |
| Results/Dividend | To consider and take on record the Audited Financial Results for the quarter, January 1, 2013 to March 31, 2013 and the year ended March 31, 2013 and to consider recommendation of Dividend, if any, for the year ended March 31, 2013. |
| Board meeting Rescheduled | The Company had informed the Exchange regarding the meeting of the Board of Directors of the Company scheduled to be held on May 03, 2013 To consider and take on record the Audited Financial Results for the quarter, January 1, 2013 to March 31, 2013 and the year ended March 31, 2013 and to consider recommendation of Dividend, if any, for the year ended March 31, 2013 and also informed dated May 03, 2013 about the postponement of the said Board Meeting. The Company has now informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 14, 2013, inter alia, to consider and take on record the Audited Financial Results for the quarter, January 01, 2013 to March 31, 2013 and the year ended March 31, 2013. At the said meeting, the Board of Directors will also consider recommendation of Dividend, if any, for the year ended March 31, 2013. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2013. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2013. |
| Others | Inter alia, to transact the following:(1) To consider a Scheme of Amalgamation of Wyeth Limited with the Company.(2) To consider declaration of Interim Dividend. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2013. |
| Results/Dividend | Inter alia, to consider and take on record the Audited Financial Results for the quarter January 1, 2014 to March 31, 2014 and for the year ended March 31, 2014. At the said meeting, the Board of Directors will also consider recommendation of final Dividend, if any, for the year ended March 31, 2014. The Trading Window for trading in the Equity shares of the Company is closed from April 23, 2014 to May 2, 2014, both days inclusive. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2014. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from July 15, 2014 to July 25, 2014, both days inclusive. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2014. Further Trading Window for trading in the Equity shares of the Company will be closed from October 22, 2014 to November 7, 2014, both days inclusive. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2014. |
| Results/Dividend | inter alia, to consider and take on record the Audited Financial Results of the Company for the quarter January 1, 2015 to March 31, 2015 and for the financial year ended March 31, 2015. Further, the Board of Directors will also consider recommendation of dividend, if any, for the financial year ended March 31, 2015. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter ended June 30, 2015. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2015. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2015. |
| Results/Dividend | inter alia, to consider and take on record the Audited Financial Results of the Company for the quarter January 1, 2016 to March 31, 2016 and for the financial year ended March 31, 2016. At the said meeting, the Board of Directors will also consider recommendation of dividend, if any, for the financial year ended March 31, 2016. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2016. |
| Results | Inter alia, to consider and take on record the unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2016. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from October 26, 2016 to November 6, 2016, both days inclusive. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2016. |
| Results/Dividend | inter alia, to consider and take on record the Audited Financial Results of the Company for the quarter January 1, 2017 to March 31, 2017 and for the financial year ended March 31, 2017. At the said meeting, the Board of Directors will also consider recommendation of dividend, if any, for the financial year ended March 31, 2017. Further that the Trading Window for trading in the Equity shares of the Company will be closed from April 27, 2017 to May 8, 2017, both days inclusive. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter ended June 30, 2017. |
| Results | inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. |
| Results | Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | To consider Interim dividend for the Financial Year ended March 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | Board Meeting for consideration and to take on record the Unaudited Financial Results for the quarter and half year ended September 30, 2021. |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Board Meeting for consideration and to take on record the Unaudited Financial Results for the quarter ended June 30, 2022. |
| Dividend | Board Meeting to consider declaration of Interim Dividend for the Financial Year ending March 31, 2023. |
| Financial results | This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 11, 2022, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2022.Pursuant to the ￢ﾀﾜPfizer Limited ￢ﾀﾓ Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders￢ﾀﾝ, the Trading Window of the Company was closed from Friday, September 30, 2022 (close of business) till 48 hours after the results are made public on November 11, 2022.We request you to kindly take the same on record. |
| Financial Results | This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 9, 2023, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended December 31, 2022.Pursuant to the Pfizer Limited Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders , the Trading Window of the Company was closed from Saturday, December 31, 2022, till 48 hours after the results are made public on February 9, 2023.We request you to kindly take the above on record. |
| Financial Results/Dividend | This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 15, 2023, inter alia, to consider and take on record the Audited Financial Results of the Company for the Financial Year ended March 31, 2023 and to consider recommendation of final dividend, if any, for the Financial Year ended March 31, 2023.Pursuant to the Pfizer Limited Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders , the Trading Window of the Company was closed from Friday, March 31, 2023 (close of business), till 48 hours after the results are made public on May 15, 2023.We request you to kindly take the same on record. |
| Financial Results | This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, August 11, 2023, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2023.Pursuant to the Pfizer Limited Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders , the Trading Window of the Company was closed from Friday, June 30, 2023 (close of business), till 48 hours after the results are made public on August 11, 2023.We request you to kindly take the same on record. |
| Financial Results | This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Saturday, October 28, 2023, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023.Pursuant to the Pfizer Limited Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders , the Trading Window of the Company was closed from Saturday, September 30, 2023, till 48 hours after the results are made public on October 28, 2023.Request you to please take the above on record. |
| Financial Results | This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 17, 2024, inter alia, to consider and take on record the Audited Financial Results of the Company for the Financial Year ended March 31, 2024 and to consider recommendation of dividend, if any, for the Financial Year ended March 31, 2024. |
| Financial Results | This is to inform you that a meeting of the Board of Directors of the Company is scheduledto be held on Monday, July 29, 2024, inter alia, to consider and take on record theUnaudited Financial Results of the Company for the quarter ended June 30, 2024.Pursuant to the Pfizer Limited Code of Internal Procedures and Conduct to Regulate,Monitor and Report Trading by Insiders , the Trading Window of the Company was closedfrom June 30, 2024, till 48 hours after the results are made public on July 29, 2024. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Share Transfers of Pfizer Limited
Voting Results of Pfizer Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 28-AUG-2024 | AGM | To receive, consider and adopt the audited financial statement of the Company for the financial year ended March 31, 2024, including the reports of the Board of Directors and Auditors thereon |
| 28-AUG-2024 | AGM | To consider and ratify the remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants for the financial year ending March 31, 2025 |
| 28-AUG-2024 | AGM | To consider and ratify the remuneration payable to Messrs. Kishore Bhatia & Associates, Cost Accountants for the financial year ended March 31, 2024 |
| 28-AUG-2024 | AGM | To consider appointment of Ms. Sonia Singh (DIN: 07108778) as an Independent Director for a term of 5 (five) consecutive years with effect from July 29, 2024 |
| 28-AUG-2024 | AGM | To consider appointment of Mr. Lakshmanan Krishnakumar (DIN: 00423616) as an Independent Director for a term of 5 (five) consecutive years with effect from July 29, 2024 |
| 28-AUG-2024 | AGM | To consider appointment of Mr. Pradip Shah (DIN: 00066242) as a Non-Executive Non-Independent Director of the Company with effect from November 10, 2024 |
| 28-AUG-2024 | AGM | Appointment of Mr. P. Rengan (DIN: 10362899) as a Director liable to retire by rotation |
| 28-AUG-2024 | AGM | To declare a dividend of Rs.35/- (350%) per equity share for the financial year ended March 31, 2024 |
| 30-MAR-2024 | Postal Ballot | Appointment of Mr. Amit Agarwal (DIN: 10465938) as a Whole-Time Director & Chief Financial Officer of the Company for a period of 5 years with effect from February 26, 2024 |
| 30-MAR-2024 | Postal Ballot | Re-appointment of Ms. Meena Ganesh (DIN: 00528252) as an Independent Director for Second Term of 5 years with effect from March 8, 2024 |
| 06-JAN-2024 | Postal Ballot | APPOINTMENT OF MR. P. RENGAN (DIN: 10362899) AS A WHOLE-TIME DIRECTOR OF THE COMPANY FOR A PERIOD OF 5 YEARS WITH EFFECT FROM OCTOBER 28, 2023 |
| 18-AUG-2023 | AGM | To receive, consider and adopt the audited financial statement of the Company fornthe financial year ended March 31, 2023, including the reports of the Board of Directors andnAuditors thereon |
| 18-AUG-2023 | AGM | To consider and ratify the remuneration payable to Messrs. RA & Co., Cost Accountants for the financial year ending March 31, 2024 |
| 18-AUG-2023 | AGM | To consider revision in the limit of commission payable to Non-Executive Directors |
| 18-AUG-2023 | AGM | Appointment of Mr. Samir Kazi (DIN: 07184083) as a Director liable to retire by rotation |
| 18-AUG-2023 | AGM | To declare a final dividend of Rs.40 (400%) per equity share for the financial year ended March 31, 2023 |
| 27-MAY-2023 | Postal Ballot | APPOINTMENT OF MS. MEENAKSHI NEVATIA (DIN: 08235844) AS A DIRECTOR AND MANAGING DIRECTOR OF THE COMPANY WITH EFFECT FROM APRIL 3, 2023 |
| 26-AUG-2022 | AGM | Adoption of audited financial statement for financial year ended March 31,2022 |
| 26-AUG-2022 | AGM | Appointment of Mr. Milind Patil, DIN: 02546815 as a Director liable to retire by rotation |
| 26-AUG-2022 | AGM | Declaration of Dividend of Rs. 35 per equity shares for financial year ended March 31, 2022 |
FAQs on Pfizer Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.